Compare MDBH & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | KZR |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 29.7M |
| IPO Year | 2023 | 2018 |
| Metric | MDBH | KZR |
|---|---|---|
| Price | $3.65 | $6.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 11.0K | ★ 34.8K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,250,398.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.16 | $3.53 |
| 52 Week High | $7.98 | $7.39 |
| Indicator | MDBH | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 61.98 |
| Support Level | $3.30 | $6.05 |
| Resistance Level | $3.69 | $6.29 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 27.12 | 64.00 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.